Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


Articles published in Cancer

Retrieve available abstracts of 80 articles:
HTML format
Text format



Single Articles


    September 2017
  1. LOPPENBERG B, Friedlander DF, Krasnova A, Tam A, et al
    Variation in the use of active surveillance for low-risk prostate cancer.
    Cancer. 2017 Sep 13. doi: 10.1002/cncr.30983.
    PubMed     Text format     Abstract available


    August 2017
  2. YANG DD, Mahal BA, Muralidhar V, Boldbaatar N, et al
    Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer.
    Cancer. 2017 Aug 22. doi: 10.1002/cncr.30948.
    PubMed     Text format     Abstract available


  3. HOFFMAN RM, Volk RJ, Wolf AMD
    Making the grade: The newest US Preventive Services Task Force prostate cancer screening recommendation.
    Cancer. 2017 Aug 22. doi: 10.1002/cncr.30941.
    PubMed     Text format    


  4. PRINTZ C
    Active surveillance helps prostate cancer patients keep quality of life, findings show.
    Cancer. 2017;123:2997.
    PubMed     Text format    


  5. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Text format     Abstract available


  6. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Text format     Abstract available


  7. GORE JL, du Plessis M, Santiago-Jimenez M, Yousefi K, et al
    Decipher test impacts decision making among patients considering adjuvant and salvage treatment after radical prostatectomy: Interim results from the Multicenter Prospective PRO-IMPACT study.
    Cancer. 2017;123:2850-2859.
    PubMed     Text format     Abstract available


    July 2017
  8. POLLACK CE, Armstrong KA, Mitra N, Chen X, et al
    A multidimensional view of racial differences in access to prostate cancer care.
    Cancer. 2017 Jul 20. doi: 10.1002/cncr.30894.
    PubMed     Text format     Abstract available


  9. EBOT EM, Gerke T, Labbe DP, Sinnott JA, et al
    Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.
    Cancer. 2017 Jul 12. doi: 10.1002/cncr.30831.
    PubMed     Text format     Abstract available


  10. HURWITZ LM, Cullen J, Kim DJ, Elsamanoudi S, et al
    Longitudinal regret after treatment for low- and intermediate-risk prostate cancer.
    Cancer. 2017 Jul 5. doi: 10.1002/cncr.30841.
    PubMed     Text format     Abstract available


  11. LEWIS DR, Chen HS, Cockburn MG, Wu XC, et al
    Early estimates of SEER cancer incidence, 2014.
    Cancer. 2017;123:2524-2534.
    PubMed     Text format     Abstract available


    June 2017
  12. SCHULMAN AA, Howard LE, Tay KJ, Tsivian E, et al
    Validation of the 2015 prostate cancer grade groups for predicting long-term oncologic outcomes in a shared equal-access health system.
    Cancer. 2017 Jun 29. doi: 10.1002/cncr.30844.
    PubMed     Text format     Abstract available


  13. PILIE PG, Johnson AM, Hanson KL, Dayno ME, et al
    Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Cancer. 2017 Jun 28. doi: 10.1002/cncr.30817.
    PubMed     Text format     Abstract available


  14. POMERANTZ MM, Spisak S, Jia L, Cronin AM, et al
    The association between germline BRCA2 variants and sensitivity to platinum-based chemotherapy among men with metastatic prostate cancer.
    Cancer. 2017 Jun 13. doi: 10.1002/cncr.30808.
    PubMed     Text format     Abstract available


  15. RIMAR KJ, Tran PT, Matulewicz RS, Hussain M, et al
    The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Cancer. 2017;123:1912-1924.
    PubMed     Text format     Abstract available


    May 2017
  16. FRENDL DM, Olumi AF
    Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30779.
    PubMed     Text format    


  17. LI TT, Shore ND, Mehra M, Todd MB, et al
    Impact of subsequent metastases on costs and medical resource use for prostate cancer patients initially diagnosed with localized disease.
    Cancer. 2017 May 23. doi: 10.1002/cncr.30784.
    PubMed     Text format     Abstract available


  18. RADHAKRISHNAN A, Grande D, Mitra N, Bekelman J, et al
    Second opinions from urologists for prostate cancer: Who gets them, why, and their link to treatment.
    Cancer. 2017;123:1027-1034.
    PubMed     Text format     Abstract available


  19. VETTERLEIN MW, Loppenberg B, Karabon P, Dalela D, et al
    Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30744.
    PubMed     Text format     Abstract available


    April 2017
  20. WALLNER LP, Jacobsen SJ
    Prostate cancer in black men: Is it time for personalized screening approaches?
    Cancer. 2017 Apr 24. doi: 10.1002/cncr.30685.
    PubMed     Text format    


  21. TSODIKOV A, Gulati R, de Carvalho TM, Heijnsdijk EAM, et al
    Is prostate cancer different in black men? Answers from 3 natural history models.
    Cancer. 2017 Apr 24. doi: 10.1002/cncr.30687.
    PubMed     Text format     Abstract available


  22. LAYNE TM, Weinstein SJ, Graubard BI, Ma X, et al
    Serum 25-hydroxyvitamin D, vitamin D binding protein, and prostate cancer risk in black men.
    Cancer. 2017 Apr 3. doi: 10.1002/cncr.30634.
    PubMed     Text format     Abstract available


    March 2017
  23. HURWITZ MD, Harris J, Sartor O, Xiao Y, et al
    Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
    Cancer. 2017 Mar 21. doi: 10.1002/cncr.30620.
    PubMed     Text format     Abstract available


  24. JACOBS BL, Yabes JG, Lopa SH, Heron DE, et al
    The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30574.
    PubMed     Text format     Abstract available



  25. Erratum: Activation of nuclear factor kappaB pathway and downstream targets survivin and livin by SHARPIN contributes to the progression and metastasis of prostate cancer.
    Cancer. 2017;123:892-893.
    PubMed     Text format    


    February 2017
  26. ADAMO MP, Boten JA, Coyle LM, Cronin KA, et al
    Validation of prostate-specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries.
    Cancer. 2017;123:697-703.
    PubMed     Text format     Abstract available


  27. GOKCE MI, Wang X, Frost J, Roberson P, et al
    Informed decision making before prostate-specific antigen screening: Initial results using the American Cancer Society (ACS) Decision Aid (DA) among medically underserved men.
    Cancer. 2017;123:583-591.
    PubMed     Text format     Abstract available


  28. ARMSTRONG AJ, Saad F, Phung, Dmuchowski C, et al
    Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
    Cancer. 2017 Feb 7. doi: 10.1002/cncr.30587.
    PubMed     Text format     Abstract available


  29. PETTERSSON A, Gerke T, Fall K, Pawitan Y, et al
    The ABC model of prostate cancer: A conceptual framework for the design and interpretation of prognostic studies.
    Cancer. 2017 Feb 2. doi: 10.1002/cncr.30582.
    PubMed     Text format     Abstract available


  30. WANG H, Hoda RS, Faquin W, Rossi ED, et al
    FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
    Cancer. 2017;125:91-103.
    PubMed     Text format     Abstract available


    January 2017
  31. LAI WS, Gordetsky JB, Thomas JV, Nix JW, et al
    Factors predicting prostate cancer upgrading on magnetic resonance imaging-targeted biopsy in an active surveillance population.
    Cancer. 2017 Jan 31. doi: 10.1002/cncr.30548.
    PubMed     Text format     Abstract available


  32. KIM H, Kalchman I, Santiago-Jimenez M, Lehrer J, et al
    Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.
    Cancer. 2017 Jan 31. doi: 10.1002/cncr.30580.
    PubMed     Text format     Abstract available


  33. WILLIAMS SB, Huo J, Chamie K, Smaldone MC, et al
    Discerning the survival advantage among patients with prostate cancer who undergo radical prostatectomy or radiotherapy: The limitations of cancer registry data.
    Cancer. 2017 Jan 18. doi: 10.1002/cncr.30506.
    PubMed     Text format     Abstract available


  34. BERNARD B, Muralidhar V, Chen YH, Sridhar SS, et al
    Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
    Cancer. 2017 Jan 5. doi: 10.1002/cncr.30503.
    PubMed     Text format     Abstract available


  35. PRINTZ C
    Smokeless tobacco product may increase mortality rate in patients with prostate cancer.
    Cancer. 2017;123:190.
    PubMed     Text format    


    December 2016
  36. KLAASSEN Z, Howard LE, de Hoedt A, Amling CL, et al
    Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer.
    Cancer. 2016 Dec 27. doi: 10.1002/cncr.30505.
    PubMed     Text format     Abstract available


  37. DESS RT, Jackson WC, Suy S, Soni PD, et al
    Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
    Cancer. 2016 Dec 21. doi: 10.1002/cncr.30519.
    PubMed     Text format     Abstract available


  38. GULATI R, Albertsen PC
    Insights from the PLCO trial about prostate cancer screening.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30472.
    PubMed     Text format    


  39. PINSKY PF, Prorok PC, Yu K, Kramer BS, et al
    Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.
    Cancer. 2016 Dec 1. doi: 10.1002/cncr.30474.
    PubMed     Text format     Abstract available


    November 2016
  40. CHEN RC
    Lymph node-positive prostate cancer-From middle child to the new frontier.
    Cancer. 2016 Nov 8. doi: 10.1002/cncr.30374.
    PubMed     Text format    


  41. JEGADEESH N, Liu Y, Zhang C, Zhong J, et al
    The role of adjuvant radiotherapy in pathologically lymph node positive prostate cancer.
    Cancer. 2016 Nov 8. doi: 10.1002/cncr.30373.
    PubMed     Text format     Abstract available


  42. FRANCINI E, Taplin ME
    Prostate cancer: Developing novel approaches to castration-sensitive disease.
    Cancer. 2016 Nov 1. doi: 10.1002/cncr.30329.
    PubMed     Text format     Abstract available


    September 2016
  43. KEARNS JT, Gore JL
    Prostate cancer screening: Do guidelines matter?
    Cancer. 2016 Sep 22. doi: 10.1002/cncr.30331.
    PubMed     Text format    


  44. REKOSKE BT, McNeel DG
    Immunotherapy for prostate cancer: False promises or true hope?
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30250.
    PubMed     Text format     Abstract available


  45. LORIOT Y, Fizazi K, de Bono JS, Forer D, et al
    Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.
    Cancer. 2016 Sep 20. doi: 10.1002/cncr.30336.
    PubMed     Text format     Abstract available


  46. HOLMES JA, Bensen JT, Mohler JL, Song L, et al
    Quality of care received and patient-reported regret in prostate cancer: Analysis of a population-based prospective cohort.
    Cancer. 2016 Sep 13. doi: 10.1002/cncr.30315.
    PubMed     Text format     Abstract available


  47. ALIBHAI SM, Timilshina N, Duff-Canning S, Breunis H, et al
    Effects of long-term androgen deprivation therapy on cognitive function over 36 months in men with prostate cancer.
    Cancer. 2016 Sep 1. doi: 10.1002/cncr.30320.
    PubMed     Text format     Abstract available


    August 2016
  48. WHITNEY CA, Howard LE, Amling CL, Aronson WJ, et al
    Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
    Cancer. 2016 Aug 9. doi: 10.1002/cncr.30221.
    PubMed     Text format     Abstract available


  49. KOVTUN KA, Chen MH, Braccioforte MH, Moran BJ, et al
    Race and mortality risk after radiation therapy in men treated with or without androgen-suppression therapy for favorable-risk prostate cancer.
    Cancer. 2016 Aug 4. doi: 10.1002/cncr.30224.
    PubMed     Text format     Abstract available


    July 2016
  50. CARLSSON SV, de Carvalho TM, Roobol MJ, Hugosson J, et al
    Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
    Cancer. 2016 Jul 26. doi: 10.1002/cncr.30192.
    PubMed     Text format     Abstract available


  51. MAHAL BA, Chen YW, Muralidhar V, Mahal AR, et al
    National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?
    Cancer. 2016 Jul 19. doi: 10.1002/cncr.30205.
    PubMed     Text format     Abstract available


  52. TURNER AR, Lane BR, Rogers D, Lipkus I, et al
    Randomized trial finds that prostate cancer genetic risk score feedback targets prostate-specific antigen screening among at-risk men.
    Cancer. 2016 Jul 19. doi: 10.1002/cncr.30162.
    PubMed     Text format     Abstract available


  53. JACOBS BL, Lopa SH, Yabes JG, Nelson JB, et al
    Association of functional status and treatment choice among older men with prostate cancer in the Medicare Advantage population.
    Cancer. 2016 Jul 5. doi: 10.1002/cncr.30184.
    PubMed     Text format     Abstract available


    June 2016
  54. WANG K, Sheets NC, Basak R, Chen RC, et al
    Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30154.
    PubMed     Text format     Abstract available


  55. KASUYA G, Ishikawa H, Tsuji H, Nomiya T, et al
    Significant impact of biochemical recurrence on overall mortality in patients with high-risk prostate cancer after carbon-ion radiotherapy combined with androgen deprivation therapy.
    Cancer. 2016 Jun 28. doi: 10.1002/cncr.30050.
    PubMed     Text format     Abstract available


    May 2016
  56. HALPERN JA, Sedrakyan A, Hsu WC, Mao J, et al
    Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
    Cancer. 2016 May 25. doi: 10.1002/cncr.30101.
    PubMed     Text format     Abstract available


  57. MCPARTLIN AJ, Glicksman R, Pintilie M, Tsuji D, et al
    PMH 9907: Long-term outcomes of a randomized phase 3 study of short-term bicalutamide hormone therapy and dose-escalated external-beam radiation therapy for localized prostate cancer.
    Cancer. 2016 May 24. doi: 10.1002/cncr.30093.
    PubMed     Text format     Abstract available


  58. FALCHOOK AD, Basak R, Mohiuddin JJ, Chen RC, et al
    Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
    Cancer. 2016 May 18. doi: 10.1002/cncr.30049.
    PubMed     Text format     Abstract available


  59. KEANE FK, D'Amico AV
    Androgen deprivation therapy use and risk of death in men treated with high-dose radiation for intermediate-risk prostate cancer.
    Cancer. 2016 May 18. doi: 10.1002/cncr.30048.
    PubMed     Text format    


  60. VERMA V, Mishra MV, Mehta MP
    A systematic review of the cost and cost-effectiveness studies of proton radiotherapy.
    Cancer. 2016;122:1483-501.
    PubMed     Text format     Abstract available


  61. BAKER BR, Basak R, Mohiuddin JJ, Chen RC, et al
    Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.
    Cancer. 2016 May 12. doi: 10.1002/cncr.30034.
    PubMed     Text format     Abstract available


  62. PRICE DK, Chau CH, Till C, Goodman PJ, et al
    Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.
    Cancer. 2016 May 10. doi: 10.1002/cncr.30071.
    PubMed     Text format     Abstract available


  63. SHUI IM, Wong CJ, Zhao S, Kolb S, et al
    Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes.
    Cancer. 2016 May 3. doi: 10.1002/cncr.30045.
    PubMed     Text format     Abstract available


    March 2016
  64. VIANI GA, Viana BS, Martin JE, Rossi BT, et al
    Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: A randomized clinical trial.
    Cancer. 2016 Mar 29. doi: 10.1002/cncr.29983.
    PubMed     Text format     Abstract available


  65. CHOW H, Ghosh PM, deVere White R, Evans CP, et al
    A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer.
    Cancer. 2016 Mar 28. doi: 10.1002/cncr.29927.
    PubMed     Text format     Abstract available



  66. Erratum: Long-term quality of life among Dutch prostate cancer survivors.
    Cancer. 2016;122:974.
    PubMed     Text format    


  67. PRINTZ C
    Early-stage prostate cancer, PSA screening rates decline.
    Cancer. 2016;122:825.
    PubMed     Text format    


  68. MAHAL BA, Chen YW, Efstathiou JA, Muralidhar V, et al
    National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study.
    Cancer. 2016 Mar 11. doi: 10.1002/cncr.29960.
    PubMed     Text format     Abstract available


  69. MOR V, Joyce NR, Cote DL, Gidwani RA, et al
    The rise of concurrent care for veterans with advanced cancer at the end of life.
    Cancer. 2016;122:782-90.
    PubMed     Text format     Abstract available


  70. WRIGHT BJ, Conlin AK, Allen HL, Tsui J, et al
    What does Medicaid expansion mean for cancer screening and prevention? Results from a randomized trial on the impacts of acquiring Medicaid coverage.
    Cancer. 2016;122:791-7.
    PubMed     Text format     Abstract available


    February 2016
  71. DESAUTELS D, Czaykowski P, Nugent Z, Demers AA, et al
    Risk of colorectal cancer after the diagnosis of prostate cancer: A population-based study.
    Cancer. 2016 Feb 25. doi: 10.1002/cncr.29919.
    PubMed     Text format     Abstract available


  72. PRINTZ C
    Racial difference seen in outcomes for older patients with prostate cancer.
    Cancer. 2016;122:501.
    PubMed     Text format    


  73. SANYAL C, Aprikian AG, Cury FL, Chevalier S, et al
    Management of localized and advanced prostate cancer in Canada: A lifetime cost and quality-adjusted life-year analysis.
    Cancer. 2016 Feb 1. doi: 10.1002/cncr.29892.
    PubMed     Text format     Abstract available


  74. TEVAARWERK AJ, Lee JW, Terhaar A, Sesto ME, et al
    Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study.
    Cancer. 2016;122:438-46.
    PubMed     Text format     Abstract available


    January 2016
  75. FILSON CP, Natarajan S, Margolis DJ, Huang J, et al
    Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
    Cancer. 2016 Jan 7. doi: 10.1002/cncr.29874.
    PubMed     Text format     Abstract available


    December 2015

  76. Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, Boffetta P and Freedland SJ. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortalit
    Cancer. 2015;121:4272.
    PubMed     Text format    



  77. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R and Freedland SJ. Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE study.
    Cancer. 2015;121:4271.
    PubMed     Text format    


    November 2015
  78. NYROP KA, Deal AM, Williams GR, Guerard EJ, et al
    Physical activity communication between oncology providers and patients with early-stage breast, colon, or prostate cancer.
    Cancer. 2015 Nov 13. doi: 10.1002/cncr.29786.
    PubMed     Text format     Abstract available


    September 2015
  79. DREYFUS M, Wion D
    Investigating the relationship between vitamin D and cancer requires dosing the bioavailable nonhydroxylated vitamin D storage in cancer tissues.
    Cancer. 2015;121:3362-3.
    PubMed     Text format    


  80. SHUI IM, Giovannucci E
    Reply to investigating the relationship between vitamin d and cancer requires dosing the bioavailable nonhydroxylated vitamin d storage in cancer tissues.
    Cancer. 2015;121:3363-4.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: